Abstract -Monoclonal antibodies may be s e l e c t i v e l y functionalised with macrocyclic ligands, permitting t h e transport of an imaging o r c t o t o x i c metal radionuclide s p e c i f i c a l l y t o a tumour. Antibodies conju ated t o p13] and [14]-membered tetraazamacrocycles allow 64Cu o r 67Cu labefled antibody t o be used f o r imaging or therapy.
INTRODUCTION
An important f e a t u r e of modern medical technology has been t h e development of monoclonal antibodies which when injected bind firmly t o tumour associated compounds (antigens) ( r e f . 1) . Although such antibodies themselves a r e r a r e l y cytotoxic, they can function as s p e c i f i c c a r r i e r s f o r t h e transport of ima ing o r cytotoxic agents t o tumours f o r use i n c l i n i c a l diagnosis o r therapy. A radionucFide-antibody conjugate can be used f o r both imaging (e.g. a 7 o r p' emitter) or therapy (e.g. a /I-o r a-emitter) but i n both cases it i s e s s e n t i a l t h a t t h e radionuclide does not dissociate from t h e antibody conju a t e , i n vivo. Conventionally the metal radionuclide has been complexed by an acyclic chelate t e . . EDTA o r DTPA) which is covalently linked t o t h e antibody. None of these chelates is afequate because t h e metal tends t o d i s s o c i a t e i n vivo. In p a r t i c u l a r t h e pathway f o r metal l o s s involves acid (or metal)-catalysed dissociation so t h a t i n t h e l i v e r and other t i s s u e s of l o c a l l y low-pH metal loss will occur readily. These problems may be obviated by using judiciously chosen macrocyclic ligands which tend t o form more k i n e t i c a l l y i n e r t complexes with metals.
For radioimmunoscintigraphy, t h e most promising radionuclides are 9 9 m T~ ( t i 6.02h, 7) , ll1J.n (ti 2.83d, 7) f o r y s c i n t i g r a p h y and G4Cu ( t t 12.8h, p') f o r position emission tomography. Both copper and technetium (as TcO2+) are well-known t o form thermodynamically s t a b l e and k i n e t i c a l l y i n e r t complexes with 1,4,8,11-tetraazacyclotetradecane (cyclam) ( r e f . 2). Our i n i t i a l e f f o r t s therefore were centred on attachin functionalised t e t r a -a z a macrocycles s e l e c t i v e l y t o t h e antibody. The r e s u l t a n t antiboiy-macrocycle conju a t e s have been radiolabelled i n aqueous solution and t h e i r s t a b i l i t examined i n b i o i i s t r i b u t i o n studies in animals. The antibody used i n t h i s work was B72.3 wiich binds s e l e c t i v e l y t o tumourassociated glycoprotein found i n human breast and colorectal cancers ( r e f s . 3 and 4 ) .
SYNTHESIS AND LINKAGE
A s e t of f o u r t e t r a -a z a macrocycles was chosen f o r t h e i n i t i a l work usin c a r r i e r -f r e e 64Cu.
Each bears on exocyclic primary amino group f o r atta.chment t o t h e antibofy ( r e f . 5 ) . Both 1 and 2 were conveniently prepared by reaction of t h e corresponding l i n e a r tetraaniine with diethyl p-cyanobenzylmalonate followed by reduction with borane-tetrahydrofuran. The related cycles 3 and 4 bearing a phenolic substituent which may a c t as a f i f t h 'axial' donor ( r e f , 6 ) ,
were synthesised by condensation of 6-cyanocoumarin with the appropriate tetraamine followed b borane reduction (Schem (293 K, p = 0.1) were determined spectrophotometrically for 3 and 4 respectively.
The next problem was to effect a selective linka e of these macrocycles to the antibody.
ligands involved the use of aryl isothiocyanates or a-bromoamides (refs. 7 and 8). was suitable in this case, nor are they intrinsically chemoselective as they react indiscriminately with antibod primar amine and thiol residues. A bifunctional linker molecule was sought which could be selectively attached to the primary amine group and which bore a second functional group for reaction with a thiol residue on the antibody. 4) vinyl pyridine derivative f! was synthesised for this urpose (Scheme 2):
are unaffected under these conditions (ref. 5). It was therefore possible to form an amide bond by reaction of the cycles 1-4 with the active ester of 5 , generating stable and isolable vinylpyridine intermediates 6 and 2. These were susceptible to attack by thiol residues on the antibody to yield stable macrocycle-antibody conjugates.
Free thiol groups on the antibody may be generated either by recombitant antibody methods, by the cleavage of the antibody disulphide links to generate F(ab)' fragments or by treatment with 2-iminothiolane. This latter route was followed first and the modified antibody was reacted with the functionalised macrocycles 6 and 1 to yield a stable thioether link between the macrocycle and the antibod .
measured spectrof luorimetrically rather than by conventional l4C radiolabelling methods) after exhaustive hydrolysis (6M H 6 1) of the antibody conjugate followed by a standard ortho-phthalaldehyde assay (ref. 9) of the resultant macrocyclic primary amine residues in 1-4.
. In 3 and 4 the diprotonated N4 ring assists the ionisation of tie exocyclic phenol by stibi '1 ising the resultant phenolate anion and pK,'s of 8.82 and 8.71
Other approaches which have been advocated for t fl e attachment of C-functionalised EDTA or DTPA
Neither
The 2-(and it reacts selectively with thiol groups in the pH range 5 to 9 whi P e primary and secondary amine groups
The number of macrocycles linked to each antibody was U to three macrocycles per antibody were measured typically, the detection limit was mol dm-3, and no diminution of immunoreactivity was observed at this level of
LABELLING METHODS AND KINETICS
The introduction of the metal radioisotope into the macrocycle-antibod conjugate needs to be effected both rapidly and selectively in order to optimise the radiolaiellin yield and obviate non-specific metal binding to the protein. This i s particularly difficult with 99mTc labelling (ti 6.02 h), as reaction of 'reduced technetium' (derived from Tc04' in presence of stannous ions) with the macroc cles 1 and 2. in particular is sluggish in the A range 7 to 9. incorporation of 99mTc gy 3 [lo0 pM] was observed (hplc) after 30 minutes at pH 8.95.
However, under these conditions, there is appreciable 'non-specif ic' binding of technetium by the protein. It is necessary therefore to form the technetium(V) dioxo complexes of the vinyl pyridine conjugates 6 and 7 & to reaction with the antibody. This pre-labelling strategy indeed results in a specifically labelled antibody and in tumour-bearing mice the tumour to blood and tumour to liver ratios were very similar to those obtained with 1251-labelled B 72.3 antibod . The limiting feature of this approach is that two separate steps are involved with a quickly decayin radioisotope, so that unless the linkage and purification steps are fast (< 2 h) the pverafl radiolabelling yield is low (< 10%). 
ii) SOU,/THF
The s i t u a t i o n is more straightforward with copper.
presence of an anionic carboxylate buffer -by t h e macrocycles 1-4 remains f a s t even at pH 4
Under these conditions, non-specific binding of Cu2+ t o t h e protein is minimised.
strong above pH 5, but at lower pH, f r e e Cu2+ does not bind ( r e f . 11 . The rate of t h e forward rate of association optimised. The more important f e a t u r e s of t h e work a r e as follows:-Binding of copper -p a r t i c u l a r l y i n the .
ref: e t t i t , lo) f o r example, has shown t h a t f o r various t y p i c a l tetrapeptides complexation of Cult is
incorporation of copper by ligands 1-4 has been studied by stopped-f 1 ow spectrophotometry, and (a) binding of Cu2' by t h e [13]-N4 system is f a s t e s t ( r e f . 10).
(b) rate is dependent on t h e nature of t h e buffer used e.g. r a t e i n succinate > c i t r a t e >> acetate.
(c) observed rate is dependent upon succinate concentration i n pH range 3.6 + 5.7
(d) t h e rates increases with decreasing ionic strength and l o t s of log k versus
Jr/l + Jr give s t r a i g h t l i n e s w i t h slopes of -2 (pH 5.77 f a l l i n g t o -1.4 (pH (e) t h e r a t e increases with temperature q u i t e steeply (E = 63 kJ mol-l f o r Cu2+/succinate/ [13] -N4).
3.7) *
Under t h e pseudo-first-order conditions used (L >_ 10 Cu2';
t h e ionic strength dependence indicates t h a t t h e species involved i n t h e rate-determinin step a r e of opposite char e. This accords with predominant reation of [Cu succinate 2 1 2 -witf using 'SdERQUAD' t o com Ute t h e refined formation constants ( p values f o r Cu(succ), C U ( S U C C )~~-and HCu(succy2-are 2.59, 4.37 and 9.62 resepctively [298 K, I = 0.11 i.e. t h e dianionic species is > 50% protonated below pH 5.25). -not dissociate from t h e antibody conjugate i n vivo:
p r e f e r e n t i a l l y accumulate i n t h e l i v e r and kidneys. ideally suited therefore f o r use i n 64Cu positron emission tomography s t u d i e s .
Animal biodistribution data a r e i f f r e e Cu2+ is injected it tends t o Such an antibody-macrocycle conjugate is mininiise non-specific copper bin ! i ing t o t h e antibody. These data suggest t h a t t h e Cu2+ does
TOWARDS THERAPY
In order t o s e l e c t i v e l y k i l l a tuinour by these methods (radioimmunotherapy] a D-6"' a )
radiolablelled antibody conju a t e is needed t o s e l e c t i v e l y d e l i v e r a s t e r i i s i n g ose of radiation, without a f f e c t i n g f e a l t h y t i s s u e . Possible therapeutic radioisotopes a r e l i s t e d in Table 2 , including 67Cu -f o r which t h e described systems apply. Unfortunately supply of t h i s radioisotope i s i n t e r m i t t e n t , while goy is readily available from a 9OSr generator. Several macrocycles have been screened f o r t h e i r a b i l i t y t o both quick1 bind yttrium and t o form a complex which is s t a b l e i n vivo. The most promising is t h e 412r-N4 tetracarboxylate 8, well known t o form k i n e t i c a l l y i n e r t 1antha.niide complexes ( r e f . 1 ) . The synthesis of a c h i r a l C-functionalised derivative 9 using L-lysine as a precursor has been c a r r i e d out (Scheme 3 ) .
The use of Cu2+ t o protect t h e diethylenetriamine sub-unit permits s e l e c t i v e acylation of the €-amino group. poly-aza macrocyclic ligands.
conjugates of ligands such as 9 with t h e goal of devising a practicable and safe approach t o radioimmunotherapy i n human p a t i e n t s .
Such a route is generally applicable t o t h e synthesis of C-functionalised Trials a r e underway t o eva.lua.te t h e u t i l i t y of antibody 
